**BURKINA FASO**

**CERVICAL CANCER PROFILE**

### Morbidity and Mortality

- Crude cervical cancer incidence per 100,000 women (2020): 10.8
- Age-standardized cervical cancer incidence per 100,000 women (2020): 18.2
- Cumulative risk of cervical cancer, ages 0-74 (2020): 2.0%
- Cervical cancer deaths (2019): 2,100
- Cervical cancer mortality-to-incidence ratio (2020): 0.74
- Population-based cancer registry exists (2021): Yes

### Primary Prevention

**HPV vaccination programme coverage among girls (2020)**

Programme coverage: No data
Coverage by age 15: No data

HPV vaccination is not included in the national vaccination schedule

**HPV vaccination programme (2020):**

- HPV included in national vaccination programme: No
- Scale of vaccination programme: -
- Year of introduction: -
- Primary target cohort: -

**Related risk factors:**

- Tobacco use prevalence, women aged 15+ years (2020): 6%
- Condom use at last high-risk sex (2010): 68%
- HIV incidence per 1000, women aged 15+ years (2020): 0.08

### Secondary Prevention

- National screening programme for cervical cancer exists (2021): Yes
- Primary screening test used (2021): VIA
- Target age range of programme (2021): 25-48 years
- Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
- Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

### Treatment and Supportive Care

- National guidelines on cervical cancer management exist (2021): Yes

**Cancer diagnosis and treatment services generally available (2021):**

- Cancer centre or cancer department at tertiary level: Yes
- Pathology services (laboratories): Yes
- Cancer surgery: Yes
- Chemotherapy: Yes
- Radiotherapy: No

**Palliative care for patients with NCDs in the public health system generally available (2021):**

- In primary health care facilities: No
- In community or home-based care: No

### WHO Cervical Cancer Elimination Strategy Targets for 2030

- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
- 90% of women identified with cervical disease receive treatment

ND = data not available

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.

---

**World Health Organization - Cervical Cancer Country Profiles, 2021**